A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Key facts

Sponsor

ECOG-ACRIN Cancer Research Group

Principal Investigator

Nina D Wagner-Johnston, MD

ECOG-ACRIN Cancer Research Group

Intervention

Acalabrutinib(drug)

Enrollment

360 target

Eligibility

18-70 years · All sexes

Timeline

2019 – 2026

Study locations (30)

• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
• CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
• Kaiser Permanente-Anaheim, Anaheim, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Mantle cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07377578
  A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
  Guangzhou Lupeng Pharmaceutical Company LTD.
• RECRUITINGPHASE2NCT07272499
  Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
  Ruijin Hospital
• RECRUITINGPHASE2NCT07029737
  A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
  AstraZeneca
• RECRUITINGNANCT07257510
  Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
  Peking University Third Hospital
• RECRUITINGPHASE2NCT06846489
  Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
  Sun Yat-sen University
• RECRUITINGPHASE3NCT06742996
  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
  BeOne Medicines
• RECRUITINGNCT06788652
  A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• RECRUITINGPHASE2NCT06522386
  GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
  M.D. Anderson Cancer Center

See all trials for Mantle cell lymphoma →